Verona Pharma (Verona Pharma) Debt-to-Equity

: 0.21 (As of Dec. 2023) 中文

View and export this data going back to 2017. Start your Free Trial

Verona Pharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1.18 Mil. Verona Pharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $50.15 Mil. Verona Pharma's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $249.28 Mil. Verona Pharma's debt to equity for the quarter that ended in Dec. 2023 was 0.21.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Verona Pharma's Debt-to-Equity or its related term are showing as below:

VRNA' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.03 Med: 0.04 Max: 0.21
Current: 0.21

During the past 13 years, the highest Debt-to-Equity Ratio of Verona Pharma was 0.21. The lowest was 0.03. And the median was 0.04.

VRNA's Debt-to-Equity is ranked worse than
57.28% of 1072 companies
in the Biotechnology industry
Industry Median: 0.15 vs VRNA: 0.21

Verona Pharma Debt-to-Equity Historical Data

The historical data trend for Verona Pharma's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verona Pharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

0.03

0.04

0.05

0.21

Verona Pharma Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity																0.05	0.07	0.08	0.08	0.21

Competitive Comparison

For the Biotechnology subindustry, Verona Pharma's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Verona Pharma Debt-to-Equity Distribution

For the Biotechnology industry and Healthcare sector, Verona Pharma's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Verona Pharma's Debt-to-Equity falls into.

Verona Pharma Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Verona Pharma's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.18	+	50.149)	/	249.283
	=	0.21

Verona Pharma's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.18	+	50.149)	/	249.283
	=	0.21

Verona Pharma (NAS:VRNA) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Verona Pharma Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Verona Pharma's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Verona Pharma (Verona Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Verona Pharma PLC (NAS:VRNA) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

I9SA:Germany

Address

3 More London Riverside, London, GBR, SE1 2RE

Website

https://www.veronapharma.com

Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma. The company is engaged in pharmaceutical development.

Executives

Martin Edwards	director	15 NEW ENGLAND EXECUTIVE PARK, BURLINGTON MA 01803
David R Ebsworth	director	C/O CURAGEN CORP, 555 LONG WHARF DR. 11TH FL., NEW HAVEN CT 06511
Kathleen A. Rickard	officer: Chief Medical Officer	C/O VERONA PHARMA PLC, 3 MORE LONDON RIVERSIDE, LONDON X0 SE1 2RE
Christina Ackermann	director	C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Claire Poll	officer: General Counsel	C/O VERONA PHARMA PLC, 3 MORE LONDON RIVERSIDE, LONDON X0 SE1 2RE
Mark W Hahn	officer: Chief Financial Officer	6340 QUADRANGLE DRIVE, SUITE 100, CHAPEL HILL NC 27517
David Zaccardelli	director, officer: President and CEO	300 TRI STATE INTERNATIONAL, SUITE 272, LINCOLNSHIRE IL 60069
Orbimed Advisors Llc	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Rishi Gupta	director, 10 percent owner	C/O CHEMOCENTRYX, INC., 850 MAUDE AVENUE, MOUNTAIN VIEW CA 94043
Access Industries Holdings Llc	10 percent owner	C/O ACCESS INDUSTRIES MANAGEMENT, LLC., 730 FIFTH AVENUE, 20TH FLOOR, NEW YORK NY 10019
Ai Biotechnology Llc	10 percent owner	C/O ACCESS INDUSTRIES, INC., 40 WEST 57TH STREET, 28TH FLOOR, NEW YORK NY 10019
Access Industries Management, Llc	10 percent owner	730 FIFTH AVENUE, NEW YORK NY 10019
Len Blavatnik	10 percent owner	C/O ACCESS INDUSTRIES, 730 FIFTH AVENUE, NEW YORK NY 10019
James Aloysius Brady	director	C/O VERONA PHARMA PLC, 3 MORE LONDON RIVERSIDE, LONDON X0 SE1 2RE
Lisa Deschamps	director	C/O VERONA PHARMA PLC, 3 MORE LONDON RIVERSIDE, LONDON X0 SE1 2RE